DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial - Holmen, Stine; Manintveld, Olivier; Damman, Kevin; Braun, Oscar; Löfman, Ida Haugen; Szymanski, Mariusz; Ravnestad, Håvard; Gude, Einar; Bjørkelund, Elisabeth; Andreassen, Arne K.; Gullestad, Lars; Broch, Kaspar; et al. (American Heart Journal, 2026)